Cadherins are transmembrane glycoproteins that mediate Ca 2+ -dependent homophilic cell-cell adhesion and play a crucial role in proliferation, differentiation and cell transformation. The goal of this study was to understand why R-cadherin is found in rhabdomyosarcomas, tumors of skeletal muscle origin, while it is absent in normal myoblasts. We show that R-cadherin Therefore, the properties of R-cadherin make it an attractive target for therapeutic intervention in rhabdomyosarcomas.
Introduction
Cadherins are homophilic cell-cell adhesion molecules essential for the organization of cells into tissues during embryonic development. They are also involved in cell growth, migration and differentiation. Cadherins are highly conserved transmembrane glycoproteins that mediate homotypic cell-cell adhesion through their extracellular domain. The cadherin cytoplasmic domains provide F-actin cytoskeleton attachment points via association of catenins and other cytoskeletal associated proteins (1) . These adhesive receptors regulate diverse functions, beyond the basic adhesive process, including intracellular signaling events (2) . In particular, cadherins activate Rho-family GTPases and participate in receptor tyrosine kinase signaling (3) . Developing skeletal muscles express N-, M-, R-cadherins and cadherindependent adhesion is required for a variety of cellular events. N-cadherin-dependent intercellular adhesion has a major role in the cell cycle exit and in the induction of the skeletal muscle differentiation program (4) (5) (6) (7) . N-cadherin regulates RhoA and Rac1, two Rho GTPases whose activity needs to be tightly controlled to allow myogenesis induction (8) .
Indeed, RhoA is activated in a N-cadherin-dependent manner which allows Serum Response Factor-dependent genes expression and myogenesis induction. In contrast, N-cadherin activation decreases Rac1 which is known to inhibit myogenesis by preventing the withdrawal of myoblasts from the cell cycle (9, 10) . During embryonic development M-cadherin is expressed later than N-cadherin. Its expression increases at the onset of secondary myogenesis, and it has been implicated in terminal myoblast differentiation, mainly during myoblast fusion (11) . R-cadherin is detected in somites and limbs, and it is localized at the cell-cell contacts of primary myoblasts during primary myogenesis, as well as at the primary myotube/secondary myoblast boundaries during secondary myogenesis (12) . R-cadherin expression is lost in adult muscles and is found expressed in rhabdomyosarcoma (RMS), a highly malignant soft-tissue tumor committed to the myogenic lineage, but arrested prior to terminal differentiation (13) . RMS are divided into two major histological subtypes, alveolar and embryonal (14) ; both express R-cadherin. R-cadherin expression in RMS is accompanied by a decrease in the expression of N-and M-cadherin which is reminiscent of the cadherin switching observed in tumorigenesis, particularly in metastasis (15) (16) . Indeed, cadherin switching is often observed in the epithelium-to-mesenchyme transition (EMT) during normal embryonic development and when cancer cells invade adjacent tissues (17) (18) (19) . R-cadherin was first found to be expressed in the chick embryonic retina and, later, was also detected, besides skeletal muscle, in heart, kidney, thymus and lung during development (12, (20) (21) (22) . Rcadherin mRNA has been detected in bladder and prostate carcinomas and its expression in various cell lines downregulates expression of other cadherins (23) (24) (25) . Conversely, Rcadherin is silenced by promoter methylation in gastrointestinal tumors (26) . This suggests that the cellular context is important for R-cadherin-induced downstream effects.
Here we show that R-cadherin expression in C2C12 cell line results in myogenesis inhibition and myoblast transformation. On the contrary, inhibition of R-cadherin expression by siRNA decreases the transformation potential of RMS cells. Furthermore, we demonstrate that Rcadherin-mediated adhesion increases Rac1 activity and that R-cadherin-induced myoblast transformation is dependent upon Rac1 activation. Finally, we evidence a cadherin switch induced by R-cadherin with down-regulation of the endogenous expression of M-cadherin and delocalization of M and N-cadherin, processes mediated by Rac1.
Materials and methods

Cell Culture and Immunocytochemistry
C2C12 mouse myoblasts and the embryonic rhabdomyosarcoma cell line (ERMS) RD were grown as described (13) .
Cells growing onto 35-mm dishes were fixed in 3.7% formaldehyde in PBS followed by a 5 min permeabilization in 0.1% Triton X-100 in PBS and then incubated in PBS containing 0.1% BSA. Myogenin, troponin T and N-cadherin expression were detected as described (8, 10) . Monoclonal anti-myc (Invitrogen) and anti cyclin D1 (BD Pharmingen) antibodies were used respectively at 1:1000 and 1:500. Primary antibodies were revealed with either an Alexa Fluor 546-or an Alexa Fluor 488-conjugated goat anti-mouse or goat anti-rabbit antibodies (Molecular Probes, Interchim). Cells were stained for F-actin using TRITC conjugated phalloidin (Sigma, France). Cells were analyzed as described (8) .
The Rac1 inhibitor NSC23766 (Calbiochem, La Jolla, CA) was used at 100 µm and was added 30 h before cell harvesting, in proliferation medium.
Establishment of stable cell lines
C2C12 were transfected with either pEGFPN1 plasmid (Clontech), in which the R-cadherin cDNA was subcloned, or infected by recombinant retroviruses produced by Phoenix cells transfected with the LZRS-MS-Rcad-2Xmyc plasmid or the LZRS-MS-R(AAA)cad-2Xmyc plasmid (kindly provided by Dr. MJ. Weelock). Stably transfected cells were selected in 1 mg/ml G418 and sorted by fluorescence-activated cell sorting for GFP expression.
To produce stable RD cell lines in which R-cadherin expression is inhibited, short interfering RNA constructs were made by cloning a double strand DNA corresponding to the R-cadherin sequence (13) 
Immunoblotting and Immunoprecipitation
Cell extracts were prepared as described (8) . For immunoprecipitation, C2C12 Rcad/GFP or C2C12 Rcad/2myc cells were lysed as described previously (8) . Lysates were immunoprecipitated using a polyclonal anti-GFP
(1:250, Torrey Pines) or a monoclonal anti-myc antibody (Invitrogen, 1:1000) followed by sequential incubation with protein A-Sepharose or protein G-sepharose (Amersham). The immunoprecipitates were analyzed by immunoblotting.
BrdU incorporation
When appropriate density was reached, cells were incubated with bromodeoxyuridine (BrdU, Boehringer) and processed as described (27) .
Luciferase assay
C2C12 cells plated in 35-mm dishes (20000 cells for subconfluent condition; 50000 cells for confluent conditions) were co-transfected using the JetPEI method with 0.6 µg of construct containing the cyclin D1 promoter fused to the luciferase gene (28) and 40 ng of pRL cytomegalovirus CMV vector (renilla luciferase cytomegalovirus). For DM conditions, 250000 cells were co-transfected as soon as they were attached to the plate. Cells were induced to differentiate four hours after transfection. Forty eight hours after transfection, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega).
Plasmid construction and production of the chimeric R-cad-Fc protein
To construct the cDNA coding for the entire mouse R-cadherin ectodomain linked to the human Fc fragment (Fc), a fragment from nucleotides 1 to 2156 was amplified by PCR reaction using oligonucleotides flanked by BamHI sites and subcloned into the TOPO vector (Invitrogen). The resulting plasmid was digested with BamHI restriction enzyme and the full length ectodomain was subcloned into the BamHI site of the pREP10-Fc plasmid (kindly provided by RM Mège, Paris, France). The production of the chimeric protein corresponding to the ectodomain of R-cadherin fused to Fc fragment (R-cad-Fc) was performed as previously described (8) .
Time lapse imaging
C2C12 Rcad/GFP and C2C12 cells were analyzed to calculate their migration (29) .
Statistical analysis
For experiments with n≥30, t test was used to assess the statistical differences between two experimental conditions ( Figure 3B , 5B). For experiments where n<30 (Figures 2A, 2C , 2D, 3A, 3C and 5B), the non-parametric Mann-Whitney U test was used to assess the statistical differences between two experimental conditions. A linear regression was used to analyse the repeated data ( Figure 3A , 3D, 5C). The tumor progress is significantly different with regard to the two groups (p=0.001).
GTPase activity assays
C2C12 myoblasts or RD cells were processed as described to measure Rac1 activity (9).
Mice and xenografting
Female C3H HEN/HSD mice and athymic mice were purchased from Harlan Laboratories and used at 6-8 weeks of age. All mice were maintained at the animal facility of Centre de 
Results
R-cadherin expression inhibits myogenesis induction
To establish the role of R-cadherin in skeletal muscle cells, we made stable mouse C2C12 myoblasts expressing either R-cadherin fused to a GFP-tag (Rcad/GFP) or to a 2myc tag (Rcad/2myc). C2C12 myoblasts expressing GFP alone were used as control. The caracterization of these clones is shown in supplementary Figure 1 .
To gain further insight into the role of R-cadherin in myogenesis, we quantified the differentiation rate of parental, GFP-and Rcad/GFP-expressing myoblasts. Confluent C2C12
myoblasts were induced to differentiate by replacing the growth medium (GM) with differentiation medium (DM) and analyzed for myotube formation and expression of musclespecific proteins. Two days after serum withdrawal (D2), myotubes were present both in parental (data not shown) and GFP-expressing C2C12 cells ( Figure 1A , panel c). Numerous myotubes were visible 3-4 days after DM addition (panels d and e). In a sharp contrast, no myotubes were visible in Rcad/GFP expressing myoblasts ( Figure 1A , bottom panels) even when differentiation conditions were maintained up to 7 days (data not shown), indicating that myoblast to myotube transition is efficiently blocked and not simply delayed. Similar data were observed in a separate Rcad/GFP-expressing clone and in 3 independent Rcad/2myc-expressing clones demonstrating that these effects were not due to clonal variations or influence of the tag (data not shown).
We next examined, whether R-cadherin could affect the expression of myogenin and troponin-T, two muscle-specific proteins. As expected, myogenin and troponin T were detected after 1 day and 2 days in DM, respectively, in parental and GFP-expressing C2C12 myoblasts, while C2C12 Rcad/GFP cells faintly expressed these proteins ( Figure 1B and 1C).
Taken together, these data suggest that R-cadherin expression blocks myogenesis induction.
R-cadherin expression inhibits myoblast cell cycle exit
Since myogenic differentiation and cell cycle progression are mutually exclusive events (30),
we asked whether the failure of R-cadherin expressing C2C12 myoblasts to differentiate could be ascribed to a high proliferative rate retained in the differentiation conditions. No obvious differences in the proliferation rate of control and Rcad/GFP-expressing cells were observed in sub-confluent cells maintained in GM. In contrast, confluent Rcad/GFPexpressing C2C12 myoblasts proliferated significantly more than control cells cultured at similar density ( Figure 2A ). This effect was even sharper when cells were induced to differentiate demonstrating that R-cadherin acts positively on cell cycle progression, bypassing not only cell contact inhibition but also cell cycle exit induced by growth factor deprivation. Cyclins are key factors for cell cycle progression. Cyclin D1 plays a critical role by regulating the transit through the G1 phase of the cell cycle and its expression markedly decreases during the C2C12 myoblast differentiation process (31) . Cyclin D1 was normally expressed both in proliferating control and Rcad/GFP-expressing C2C12 myoblasts and was reduced in control cells induced to differentiate ( Figure 2B ). In contrast, cyclin D1 expression was maintained in C2C12 Rcad/GFP cells cultured in DM. The maintenance of cyclin D1 expression in Rcad/GFP-expressing cells after DM addition was confirmed also by immunocytochemistry ( Figure 2C ). To test whether sustained cyclin D1 expression was due to transcriptional regulation of the promoter, we performed luciferase assays in which parental and Rcad/GFP-expressing C2C12 were transfected with the cyclin D1 promoter fused to the luciferase reporter gene. In proliferative conditions the level of cyclin D1 activation was comparable between control and C2C12 Rcad/GFP cells ( Figure 2D ). However, upon differentiation this level of activity was maintained only in R-cadherinexpressing C2C12 myoblasts, whereas in control cells the activity of the promoter diminished. Next, we examined the level of cyclin A expression, a cyclin that acts during S phase, which is rather linked to proliferation (32) . Cyclin A was similarly maintained at high level in C2C12 Rcad/GFP-expressing myoblasts upon differentiation conditions, while was downregulated in control cells ( Figure 2B ). 
R-cadherin expression induces myoblast transformation and increases cell motility
R-cadherin expression activates Rac1 GTPase
To examine whether the R-cadherin-dependent cell-cell contacts might control the Rho GTPase activity, we used the organization of the F-actin cytoskeleton as a functional read-out Rcad/GFP myoblasts, demonstrating that R-cadherin activates the JNK pathway in myoblasts.
In parallel, we used extracts from the RMS cell line RD in which R-cadherin expression was inactivated by RNA interference. Significantly, the down-regulation of R-cadherin expression in the RMS cell line RD was accompanied by a lower Rac1 activity level, indicating that Rcadherin is partly accountable for the Rac1 activity in RD ( Figure 4D ).
Rac1 inhibition decreases R-cadherin-dependent signaling
We next investigated the effect of Rac1 inhibition on R-cadherin-dependent pathways. First, we analyzed the effect of dominant negative Rac1 (Rac1N17) on R-cadherin-induced cyclin D1 expression. C2C12 Rcad/GFP myoblasts were transfected with empty pRFP or RFPtagged Rac1N17 and induced to differentiate by addition of DM. Cells were fixed 2 days thereafter, and analyzed for cyclin D1 expression. Cyclin D1 was detected in less than 20% of cells expressing Rac1N17 ( Figure 5A , panels d-f and Figure 5B ) whereas it was expressed in almost 50% of the parental cells (data not shown) and of the cells transfected with empty pRFP ( Figure 5A , panels a-c and Figure 5B) . A comparable inhibition of R-cadherin-induced cyclin D1 expression was obtained using the specific Rac inhibitor NSC23766 ((34), data not shown). Moreover, mice injected with Rac1N17-infected C2C12 Rcad/GFP myoblasts developed significantly smaller tumors than mice injected with C2C12 Rcad/GFP cells ( Figure 5C ).
Taken together, these findings emphasize that the R-cadherin-induced Rac1 activation is critical for R-cadherin-induced cyclin D1 expression and for myoblast transformation in vivo.
R-cadherin expression down-regulates N-and M-cadherin
Cadherin switching has been implicated in tumorigenesis (15, 16) . We thus analyzed whether Cadherin switching induced by R-cadherin has been linked to competition for p120 ctn , a mechanism in which p120 ctn plays the role of a rheostat to regulate the levels of cadherin in the cell (35) . To test this hypothesis in our system we generated stable mouse C2C12 myoblasts expressing the R-cadherin mutant (Rcad-AAA) that do not interact with p120 
Discussion
The data presented here provide evidence that R-cadherin is a key player in myogenesis inhibition and myoblast transformation. R-cadherin has been detected in developing skeletal muscles and it might be implicated in the formation of this tissue since its expression can rescue striated muscle in embryonic stem cells that lack E-cadherin (12) . On the other hand, its expression in C2C12 myoblasts inhibits myogenesis induction and causes their transformation. Moreover, we have previously observed R-cadherin expression in RMS cell lines and biopsies, while this protein is absent from normal adult tissues (13) . This suggests that R-cadherin has to be tightly controlled during skeletal muscle development. In this study,
we further demonstrate that R-cadherin is a major actor of tumorigenesis and/or tumor progression in muscle cells because i) its expression is able to drive myoblast transformation Tumor cells often show a decrease in cell-cell and/or cell-matrix adhesion. An increasing body of evidence now indicates that aberrant cell adhesion is causally involved in tumor progression and metastasis, rather than merely being a consequence of it (36) . Amongst these adhesion defects, cadherin switching plays a critical role in the progression of some tumors (15) . In particular, the switch from E-to N-cadherins has been shown to enhance the motility, invasivness and metastatic potential of cancer cells (37) . Moreover, P-cadherin overexpression promotes N-cadherin downregulation and consequently facilitates the motility of pancreatic cancer cells (38) . These changes in cadherin expression not only modulate tumor cell adhesion, but also affect signal transduction and hence tumor malignancy. Such a cadherin switching was observed in RMS cell lines and biopsies since we detected R-cadherin expression concomitant with a perturbation in N-and M-cadherin function (13). Here we demonstrate that this cadherin switch is induced by R-cadherin expression in myoblasts,
suggesting that R-cadherin deregulation during muscle development might be sufficient to induce the loss of N-and M-cadherin-mediated cell-cell adhesion and to support tumour transition towards malignancy. In this regard, beside the control of myogenesis induction, N-cadherin-dependent signaling mediates contact inhibition of cell growth through the cyclindependent kinase inhibitor p27Kip1 (8, 39, 40) . p120 ctn and Rac1 play an important role in the molecular mechanisms by which R-cadherin induces N-and M-cadherin down-regulation.
Use of an R-cadherin mutant that could not bind p120 ctn does not perturb the distribution of N-and M-cadherin at the membrane of C2C12 cells as well as their ability to undergo differentiation. Since p120 ctn seems to be limiting in the cell, its binding to exogenously expressed R-cadherin could lead to the destabilization and degradation of N-and M-cadherin.
A similar mechanism has been described recently in epithelial cells where ectopic expression of R-cadherin induces down regulation of E-and P-cadherin by competition for p120 ctn (35) .
We also show that Rac1, which is activated by R-cadherin expression, is implicated in this process since Rac1 inhibition clearly restores the levels of M-cadherin in R-cadherin expressing C2C12 cells. Additional unidentified pathways might be activated downstream of R-cadherin since Rac1 activation alone is not sufficient to induce M-cadherin degradation whereas it leads to M and N-cadherin delocalization from the cell-cell contacts (Supplementary Figure 3) .
R-cadherin has recently emerged as a marker of RMS (13, 41) . It remains to be determined whether R-cadherin has been maintained due to the development stage of RMS, or whether it has been re-expressed in these cells. Interestingly, mice that express, in postnatal terminally 
